12 May 2020

The response evaluation of cancer immunotherapy requires differentiation from traditional chemotherapy; hence, it needs more precise criteria that are compatible with the observed response patterns and the well-documented mechanism of action of these novel treatments. This 30-minute presentation + 15-minute Q&A provides a review of the latest advances on imaging assessment for cancer immunotherapy evaluation in clinical trials.


  • Lesson learnt – the evolution of response criteria in immunotherapy
  • Overview of immune modified response criteria
  • Challenging cases – pitfall of imaging interpretation


  • Dr. Yan Liu, CMO, Median Technologies
  • Dr. Antoine Iannessi, Medical Director iCRO, Median Technologies